Clinical Trial Update: Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 clinical trial evaluating sonelokimab for active moderate-to-severe hidradenitis suppurativa.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Sonelokimab (sonelokimab)

Snippet

Sponsor: MoonLake Immunotherapeutics AG | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: COMPLETED